Med BioGene Posts 2009 Loss of $2.1M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostic test developer Med BioGene, which is working toward commercializing its LungExpress Dx test, earned no revenue in 2009 and took a loss on the year of US$2.1 million, the same amount it lost in 2008.

The Vancouver, BC-based company bumped up its R&D spending by 32 percent last year, from $751,000 in 2008 to $989,000 in 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.